2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2773 Real-world treatment patterns in relapsed and refractory follicular lymphoma in alberta, Canada.

Ariane Gosselin, Hardeek Patel, MD2, Seann Seto3, Mariet Stephen4, Winson Y Cheung, MD, MPH, FRCPC5
1 Abbvie, St-Laurent, Quebec, Canada
2 Abbvie, St-Laurent, Quebec, Canada
3 Abbvie, St-Laurent, Quebec, Canada
4 University of Calgary, Calgary, Alberta, Canada
5 University of Calgary, Calgary, Alberta, Canada
Background: Follicular lymphoma (FL) is characterized by a relapsing-remitting course with diminishing treatment durability across successive lines of therapy. In Canada, there is no established standard of care for relapsed/refractory (R/R) FL, and real-world treatment sequencing patterns remain poorly characterized. We conducted a population-based study to describe treatment patterns among patients with R/R FL in Alberta, Canada.

Methods: This retrospective, observational population-based cohort study used linked administrative and chart-abstracted data from the Alberta Cancer Registry. Adult patients diagnosed with grade 1-3a FL between 2010 and 2023 who received systemic therapy through May 2025 were included. Baseline and clinical characteristics were analyzed for the overall cohort. Treatment patterns across first-line (1L), second-line (2L), and third-line or later (3L+) therapy were described. Time to next treatment (TTNT) was estimated using the Kaplan-Meier method.

Results: A total of 1,418 patients were included in this study. Median age at diagnosis was 62 years (interquartile range 54-71), and 52.5% were male. Most patients were treated at academic centers (72.1%) and resided in urban settings (82.8%). In 1L, the most used regimens were bendamustine-rituximab (BR±R) (58.0%) and other rituximab-based chemoimmunotherapy (R-CIT) (29.5%). Among 1,418 patients who initiated 1L therapy, only 304 (21.4%) received 2L treatment; 219 (15.4%) died, and 895 (63.1%) remained alive but had not yet progressed to or required 2L. For the patients who received 2L treatment (N=304), treatment patterns were substantially more heterogeneous, with R-CHOP (22.0%), BR±R (12.2%), cisplatin-gemcitabine-rituximab (9.9%), cyclophosphamide etoposide-rituximab-vincristine (7.6%), R-CVP (6.2%), rituximab-lenalidomide (R2) (3.6%), and rituximab monotherapy (4.3%) utilized. Among patients receiving 2L therapy from 2022 onward (N=98), the R2 combination accounted for 11.2% of regimens. Median duration of therapy was 15.6 months in 1L and 3.3 months in 2L. Median TTNT from 1L to 2L was 46.5 months (95% confidence interval [CI] 44.4-51.8), while median TTNT from 2L to 3L was 23.3 months (95% CI 16.7-35.0). Stratified analyses demonstrated variation in TTNT by regimen type. In 1L, median TTNT was 51.4 months (95% CI 46.5-63.5) for BR±R, 41.8 months (95% CI 36.8-46.7) for R-CIT, and 35.6 months (95% CI 20.9-not reached) for rituximab monotherapy. Rituximab maintenance between 1L and 2L was observed in 3.0% of patients.

Conclusions: This population-based real-world study demonstrates relatively consistent 1L treatment patterns with BR±R but substantial heterogeneity in subsequent lines of therapy for R/R FL, where R2 is a new emerging treatment option in this setting in recent years in Alberta, Canada since the AUGMENT results became available. This uptake is consistent with R2’s inclusion in R/R FL treatment guidelines globally and ongoing clinical trial development in the 2L+ setting. Treatment durability declined with successive lines, highlighting ongoing unmet needs and the importance of developing more effective and durable therapeutic strategies, as well as optimizing sequencing strategies in R/R FL.
Ariane Gosselin: Abbvie - Current Employment